

# Volker Heinemann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3041332/publications.pdf>

Version: 2024-02-01

245  
papers

10,223  
citations

61945

43  
h-index

37183

96  
g-index

251  
all docs

251  
docs citations

251  
times ranked

12758  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KKR-0306). International Journal of Cancer, 2022, 150, 112-123.	2.3	10
2	Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KKR 0212). Journal of Clinical Oncology, 2022, 40, 72-82.	0.8	42
3	Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score. Clinical Cancer Research, 2022, 28, 1412-1421.	3.2	46
4	Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreak100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncology, The, 2022, 23, 115-124.	5.1	147
5	The role of germline polymorphisms in genes involved in the antioxidant system to predict the efficacy of cetuximab for patients with metastatic colorectal cancer (mCRC) enrolled in FIRE-3 trial.. Journal of Clinical Oncology, 2022, 40, 143-143.	0.8	0
6	The role of genetic variants involved with ferroptosis regulator genes in predicting outcomes in patients (pts) with RAS-mutant metastatic colorectal cancer (mCRC): Data from MAVERICC and TRIBE trials.. Journal of Clinical Oncology, 2022, 40, 197-197.	0.8	1
7	Efficacy of bevacizumab-based treatment in early-onset treatment-naïve metastatic colorectal cancer patients: An ARCAD database analysis.. Journal of Clinical Oncology, 2022, 40, 101-101.	0.8	0
8	Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years. European Journal of Cancer, 2022, 163, 1-15.	1.3	6
9	Novel systemic treatment approaches for metastatic pancreatic cancer. Expert Opinion on Investigational Drugs, 2022, 31, 249-262.	1.9	12
10	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI Cancer Spectrum, 2022, 6, .	1.4	3
11	Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial. Frontiers in Oncology, 2022, 12, 751453.	1.3	1
12	Strategies to successfully prevent COVID-19 outbreak in vulnerable uro-oncology patient population. Infection, 2022, , 1.	2.3	1
13	Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3). International Journal of Cancer, 2022, 150, 1341-1349.	2.3	6
14	The impact of adjuvant therapy on outcome in UICC stage I pancreatic cancer. International Journal of Cancer, 2022, , .	2.3	4
15	Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer. JNCI Cancer Spectrum, 2022, 6, .	1.4	7
16	Randomized study to investigate a switch maintenance concept with 5-FU plus bevacizumab after FOLFIRI plus cetuximab induction treatment versus continued treatment with FOLFIRI plus cetuximab: Report of a secondary endpoint of the phase-III FIRE-4 study (AIO KKR-0114).. Journal of Clinical Oncology, 2022, 40, 3519-3519.	0.8	5
17	Negative hyperselection for mutations associated with anti-EGFR antibody resistance in RAS wildtype metastatic colorectal cancer (mCRC): Evaluation of the PANAMA trial (AIO-KKR-0212), Tj ETQq1 1 0.784314 rgBT /Overlock 10 Oncology, 2022, 40, 3536-3536.	0.8	2
18	BRAF-mutant metastatic colorectal cancer: Prognostic and predictive value of primary tumor location—A pooled analysis of the AIO studies FIRE-1, CIOX, XELAVIRI, FIRE-3, and VOLFI.. Journal of Clinical Oncology, 2022, 40, 3576-3576.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Impact of age and gender on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC): Subgroup analysis of the PANAMA-study (AIO-KRK-0212).. Journal of Clinical Oncology, 2022, 40, 3567-3567.	0.8	0
20	Response to epithelial growth factor receptor inhibitor (EGFRi) treatment in patients with early-onset, treatment-naïve metastatic colorectal cancer (mCRC): An ARCAD database analysis.. Journal of Clinical Oncology, 2022, 40, 3572-3572.	0.8	1
21	Predictive and prognostic value of carcinoembryonic antigen (CEA) on maintenance therapy with 5-fluorouracil/leucovorin plus panitumumab or 5-fluorouracil/leucovorin alone in RAS wildtype metastatic colorectal cancer: Evaluation of the phase II PanaMa trial (AIO KRK 0212).. Journal of Clinical Oncology, 2022, 40, 3587-3587.	0.8	0
22	Impact of the COVID-19 pandemic on colorectal cancer (CRC) care: Data from 22 German cancer centers (CC) and the Institute of Pathology, Ruhr-University Bochum - the AIO (Working Group for Internal Tumor Therapy) (AIO-IT). Journal of Clinical Oncology, 2022, 40, 3626-3626.	0.8	0
23	Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of panitumumab (Pmab), fluorouracil and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab-FOLFOX induction in RAS wildtype metastatic colorectal cancer (mCRC): PANAMA trial (AIO-KRK-0212).. Journal of Clinical Oncology, 2022, 40, 3537-3537.	0.8	0
24	Patients' Perspective on Digital Technologies in Advanced Genitourinary Cancers. Clinical Genitourinary Cancer, 2021, 19, 76-82.e6.	0.9	12
25	Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment. Journal of Gastrointestinal Surgery, 2021, 25, 58-66.	0.9	7
26	FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. British Journal of Cancer, 2021, 124, 587-594.	2.9	79
27	NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU. Archives of Gynecology and Obstetrics, 2021, 303, 1331-1345.	0.8	11
28	Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival. International Journal of Cancer, 2021, 148, 1919-1927.	2.3	17
29	Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC study (AIO-KRK-0111). International Journal of Cancer, 2021, 148, 1428-1437.	2.3	2
30	Information, communication, and cancer patients' trust in the physician: what challenges do we have to face in an era of precision cancer medicine?. Supportive Care in Cancer, 2021, 29, 2171-2178.	1.0	12
31	The relevance of CT-based geometric and radiomics analysis of whole liver tumor burden to predict survival of patients with metastatic colorectal cancer. European Radiology, 2021, 31, 834-846.	2.3	27
32	Genetic variants involved in the lipid metabolism pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC trials.. Journal of Clinical Oncology, 2021, 39, 118-118.	0.8	0
33	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110205.	1.4	3
34	Single nucleotide polymorphisms (SNPs) in endoplasmic reticulum (ER) stress response genes to predict first-line treatment outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from the MAVERICC and FIRE-3 trials.. Journal of Clinical Oncology, 2021, 39, 103-103.	0.8	3
35	Polymorphisms of pluripotency transcription factors for predicting cetuximab efficacy in metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials.. Journal of Clinical Oncology, 2021, 39, 98-98.	0.8	0
36	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. Molecular Cancer Therapeutics, 2021, 20, 1153-1160.	1.9	1

#	ARTICLE	IF	CITATIONS
37	<i>BRAF</i> V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1386-1395.	3.0	17
38	Routine application of next-generation sequencing testing in uro-oncology – Are we ready for the next step of personalised medicine?. <i>European Journal of Cancer</i> , 2021, 146, 1-10.	1.3	5
39	Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110). <i>European Journal of Cancer</i> , 2021, 147, 128-139.	1.3	9
40	Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of <i>BRAF</i> V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3502-3502.	0.8	28
41	Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity. <i>Oncotarget</i> , 2021, 12, 982-995.	0.8	0
42	Maintenance therapy with 5-fluoruracil/leucovorin (5FU/LV) plus panitumumab (pmab) or 5FU/LV alone in <i>RAS</i> wildtype (WT) metastatic colorectal cancer (mCRC) - the PANAMA trial (AIO KRK 0212).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3503-3503.	0.8	5
43	Patient-reported quality of life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: Interim results of the TALLISUR study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3526-3526.	0.8	0
44	FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of <i>RAS</i> wild-type colorectal cancer liver metastases: The PARLIM trial (AIO KRK 0314).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3553-3553.	0.8	0
45	The role of PP2A variants to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3581-3581.	0.8	0
46	Genetic variants involved in the cGAS-STING pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3535-3535.	0.8	1
47	Consensus molecular subtypes and <i>RAS</i> status as biomarker of treatment intensity with fluoropyrimidine, bevacizumab, and irinotecan in metastatic colorectal cancer (XELAVIRI, AIO KRK) Tj ETQq1 1 0.784314 rgBto/Overlook	0.8	0
48	Treatment responses and disease dynamics in patients with untreated metastatic colorectal cancer receiving bevacizumab-based sequential versus combination chemotherapy: Analysis of a phase 3 trial (AIO KRK0110, XELAVIRI study).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3571-3571.	0.8	0
49	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 150, 133-142.	1.3	1
50	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1705-1713.	3.0	12
51	Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection ( AIO KRK 0306; FIRE 4.5). <i>International Journal of Cancer</i> , 2021, 149, 1935-1943.	2.3	3
52	Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models. <i>Genome Medicine</i> , 2021, 13, 116.	3.6	10
53	Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). <i>European Journal of Cancer</i> , 2021, 157, 71-80.	1.3	4
54	Quantitative Imaging Biomarkers of the Whole Liver Tumor Burden Improve Survival Prediction in Metastatic Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 5732.	1.7	8

#	ARTICLE	IF	CITATIONS
55	Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 391-399.	1.2	13
56	Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz060.	1.4	7
57	Cost-effectiveness of FOLFIRI+â€œcetuximab vs FOLFIRI+â€œbevacizumab in the first-line treatment of RAS-wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study. <i>Journal of Medical Economics</i> , 2020, 23, 448-455.	1.0	8
58	Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3185-3194.	0.8	233
59	Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study). <i>European Journal of Cancer</i> , 2020, 137, 81-92.	1.3	3
60	Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial. <i>European Journal of Cancer</i> , 2020, 137, 250-259.	1.3	15
61	Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). <i>Oncolmmunology</i> , 2020, 9, 1806680.	2.1	11
62	Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer â€œ translational results from the AIO-PK0104 Phase 3 study. <i>British Journal of Cancer</i> , 2020, 123, 1370-1376.	2.9	10
63	Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study. <i>Anti-Cancer Drugs</i> , 2020, 31, 856-865.	0.7	2
64	Lessons from the coronavirus disease 2019 pandemic: Will virtual patient management reshape uro-oncology in Germany?. <i>European Journal of Cancer</i> , 2020, 132, 136-140.	1.3	21
65	Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver?. <i>European Urology Focus</i> , 2020, 6, 1097-1103.	1.6	52
66	Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group â€œMolecular Diagnostics and Therapyâ€™. <i>European Journal of Cancer</i> , 2020, 135, 1-7.	1.3	23
67	Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2077-2087.	1.2	10
68	Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306. <i>Clinical Colorectal Cancer</i> , 2020, 19, 291-300.e5.	1.0	8
69	Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306. <i>Annals of Surgical Oncology</i> , 2020, 27, 2389-2401.	0.7	16
70	Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib â€œ results from a non-interventional multi-center study. <i>BMC Cancer</i> , 2020, 20, 155.	1.1	3
71	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. <i>European Journal of Cancer</i> , 2020, 131, 89-97.	1.3	9
72	Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4029-4029.	0.8	9

#	ARTICLE	IF	CITATIONS
73	Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GE) cancer.. Journal of Clinical Oncology, 2020, 38, TPS4649-TPS4649.	0.8	5
74	Prognostic and predictive impact of primary tumor sidedness in first-line trials for advanced colorectal cancer: An analysis of 7,828 patients in the ARCAD database.. Journal of Clinical Oncology, 2020, 38, 188-188.	0.8	2
75	HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).. Journal of Clinical Oncology, 2020, 38, 638-638.	0.8	51
76	A Web- and App-Based Connected Care Solution for COVID-19 In- and Outpatient Care: Qualitative Study and Application Development. JMIR Public Health and Surveillance, 2020, 6, e19033.	1.2	46
77	Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial.. Journal of Clinical Oncology, 2020, 38, 245-245.	0.8	1
78	Genetic variants involved in bromodomain-containing protein 4 (BRD4) regulating pathway to predict outcomes in patients with metastatic colorectal cancer: Results from FIRE3 and MAVERICC trials.. Journal of Clinical Oncology, 2020, 38, 232-232.	0.8	0
79	Genetic variants in immunogenic cell death (ICD) relating genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE and MAVERICC trials.. Journal of Clinical Oncology, 2020, 38, 187-187.	0.8	0
80	Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.. Journal of Clinical Oncology, 2020, 38, 190-190.	0.8	1
81	Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status: Analysis of untreated RAS-wildtype mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).. Journal of Clinical Oncology, 2020, 38, e16055-e16055.	0.8	0
82	Implementing a novel method to estimate the "Burden of Therapy" (BOTH) for patients with metastatic pancreatic cancer treated with gemcitabine plus afatinib vs. gemcitabine in the AIO ACCEPT trial.. Journal of Clinical Oncology, 2020, 38, e16786-e16786.	0.8	0
83	High amphiregulin mRNA expression is a strong prognostic biomarker with response to cetuximab in FIRE-1, CIOX, and FIRE-3.. Journal of Clinical Oncology, 2020, 38, 4026-4026.	0.8	0
84	CCR5 $\uparrow$ 32 mutation and gene expression to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC phase III trials.. Journal of Clinical Oncology, 2020, 38, 170-170.	0.8	1
85	Optimizing the Analytical Value of Oncology-Related Data Based on an In-Memory Analysis Layer: Development and Assessment of the Munich Online Comprehensive Cancer Analysis Platform. Journal of Medical Internet Research, 2020, 22, e16533.	2.1	3
86	Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. Clinical Cancer Research, 2019, 25, 134-141.	3.2	34
87	FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). Journal of Clinical Oncology, 2019, 37, 3401-3411.	0.8	132
88	Advances in cancer immunotherapy 2019 – latest trends. Journal of Experimental and Clinical Cancer Research, 2019, 38, 268.	3.5	401
89	Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). Clinical Colorectal Cancer, 2019, 18, 183-191.e3.	1.0	16
90	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. International Journal of Cancer, 2019, 145, 2082-2090.	2.3	4

#	ARTICLE	IF	CITATIONS
91	Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. <i>European Journal of Cancer</i> , 2019, 107, 100-114.	1.3	12
92	Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2019, 106, 37-44.	1.3	44
93	Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer. <i>International Journal of Cancer</i> , 2019, 144, 569-581.	2.3	19
94	BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3145-3145.	0.8	3
95	Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3511-3511.	0.8	6
96	Gender and survival benefit from initial irinotecan in metastatic colorectal cancer: Analysis of the XELAVIRI (AIOKRK0110) study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3559-3559.	0.8	1
97	Association of microRNA-21 with efficacy of cetuximab in RAS wild-type patients in the FIRE-3 study (AIO) Tj ETQq1 1 0.784314 rgBT / Over Clinical Oncology, 2019, 37, 3593-3593.	0.8	4
98	Gender and survival benefit from initial irinotecan in metastatic colorectal cancer: Analysis of the XELAVIRI (AIOKRK0110) study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 549-549.	0.8	1
99	Nintedanib versus placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: TRICC-C trialâ€”Final results from the randomized phase II trial of the AIO.. <i>Journal of Clinical Oncology</i> , 2019, 37, 666-666.	0.8	1
100	Th17 cell pathway-related genetic variants in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC, and FIRE-3.. <i>Journal of Clinical Oncology</i> , 2019, 37, 594-594.	0.8	0
101	Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 564-564.	0.8	0
102	Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE.. <i>Journal of Clinical Oncology</i> , 2019, 37, 558-558.	0.8	4
103	Evaluation of health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC): A prospective, multicenter, open-label, double-arm trial of trifluridine/tipiracil (FTD/TPI) versus best supportive care (BSC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS726-TPS726.	0.8	0
104	Effect of patient age on efficacy of FOLFIRI plus cetuximab vs bevacizumab in 1st-line treatment of metastatic colorectal cancer: An analysis of FIRE-3 (AIO KRK 0306).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3541-3541.	0.8	0
105	Genetic variants in RNA binding protein (RBP) to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE, and MAVERICC trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3545-3545.	0.8	0
106	Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Final results of the phase 1/2 TREAT-ME-1 trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14648-e14648.	0.8	0
107	Tumor dynamics with fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone as initial treatment of RAS wildtype metastatic colorectal cancer (mCRC): Central radiologic review of VOLFIâ€”A randomized, open label, phase-2 study (AIO) Tj ETQq1 1 0.784314 rgBT / Over Clinical Oncology, 2019, 37, 3541-3541.	0.8	0
108	Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3048-3048.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Association of MAPK signaling subtypes with prognostic benefit for bevacizumab in left-sided metastatic colorectal cancer (mCRC) patients treated with FOLFIRI + cetuximab / bevacizumab (FIRE-3) Tj ETQq1 1 0.7843140gBT /Over	1.0	14
110	Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinoma of the prostate. European Journal of Cancer, 2018, 95, 109-111.	1.3	5
111	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. Journal of the National Cancer Institute, 2018, 110, 638-648.	3.0	90
112	Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial. European Journal of Radiology, 2018, 100, 124-129.	1.2	2
113	The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 199-207.	1.4	17
114	Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial. International Journal of Cancer, 2018, 142, 1047-1055.	2.3	12
115	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. Clinical Cancer Research, 2018, 24, 784-793.	3.2	23
116	The DNA-polymorphism rs849142 is associated with skin toxicity induced by targeted anti-EGFR therapy using cetuximab. Oncotarget, 2018, 9, 30279-30288.	0.8	6
117	POLE gene hotspot mutations in advanced pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2161-2166.	1.2	15
118	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer, 2018, 100, 35-45.	1.3	29
119	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. Pharmacogenomics Journal, 2018, 18, 623-632.	0.9	8
120	Towards volumetric thresholds in RECIST 1.1: Therapeutic response assessment in hepatic metastases. European Radiology, 2018, 28, 4839-4848.	2.3	13
121	CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial. European Radiology, 2018, 28, 5284-5292.	2.3	17
122	mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC): A randomized phase II VOLFI trial of the AIO (AIO- KRK0109).. Journal of Clinical Oncology, 2018, 36, 3509-3509.	0.8	14
123	Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. Journal of Clinical Oncology, 2018, 36, 3576-3576.	0.8	2
124	Somatic DNA mutations, tumor mutational burden (TMB), and MSI Status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306).. Journal of Clinical Oncology, 2018, 36, 3591-3591.	0.8	12
125	Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line (1L) treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Data from the FIRE-3 (AIO KRK-0306) study.. Journal of Clinical Oncology, 2018, 36, 800-800.	0.8	1
126	Per protocol analysis and final OS update of the FIRE-3 (AIO KRK-0306) study comparing FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab.. Journal of Clinical Oncology, 2018, 36, 3508-3508.	0.8	0



#	ARTICLE	IF	CITATIONS
127	Genetic variations in the $\hat{2}M/HLA-E$ immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial.. Journal of Clinical Oncology, 2018, 36, 12107-12107.	0.8	0
128	Genetic variation in TET3 and survival in metastatic colorectal cancer (mCRC) from FIRE-3, TRIBE, and MAVERICC clinical trials.. Journal of Clinical Oncology, 2018, 36, 3575-3575.	0.8	0
129	Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer. Gastric Cancer, 2017, 20, 358-367.	2.7	4
130	Methylated free-circulating <i>HPP1</i> DNA is an early response marker in patients with metastatic colorectal cancer. International Journal of Cancer, 2017, 140, 2134-2144.	2.3	55
131	Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. British Journal of Cancer, 2017, 116, 1462-1469.	2.9	25
132	The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. European Journal of Cancer, 2017, 70, 87-98.	1.3	436
133	Response to letter entitled: Distinct metastatic patterns in colorectal cancer patients. European Journal of Cancer, 2017, 77, 1-2.	1.3	0
134	Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Oncoimmunology, 2017, 6, e1310358.	2.1	111
135	Evaluation of Visualization Using a 50/50 (Contrast Media/Glucose 5% Solution) Technique for Radioembolization as an Alternative to a Standard Sandwich Technique. CardioVascular and Interventional Radiology, 2017, 40, 1740-1747.	0.9	2
136	Single nucleotide polymorphisms in the IGF1R pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. International Journal of Cancer, 2017, 141, 383-392.	2.3	10
137	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. European Journal of Cancer, 2017, 77, 13-20.	1.3	19
138	Improving post-surgical management of resected pancreatic cancer. Lancet, The, 2017, 390, 847-848.	6.3	6
139	Prognostic Value of Preoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 After Resection of Ampullary Cancer. Journal of Gastrointestinal Surgery, 2017, 21, 1775-1783.	0.9	9
140	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncology, The, 2017, 18, 1159-1171.	5.1	293
141	Universal Genomic Testing: The next step in oncological decision-making or a dead end street?. European Journal of Cancer, 2017, 82, 72-79.	1.3	13
142	Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research. BMC Cancer, 2017, 17, 374.	1.1	1
143	Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer – A retrospective cohort study. Thrombosis Research, 2017, 157, 9-15.	0.8	49
144	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. JAMA Oncology, 2017, 3, 194.	3.4	555

#	ARTICLE	IF	CITATIONS
145	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. <i>Journal of Clinical Oncology</i> , 2017, 35, 1929-1937.	0.8	37
146	Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash. <i>Oncotarget</i> , 2017, 8, 35193-35204.	0.8	10
147	Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306). <i>Oncotarget</i> , 2017, 8, 105749-105760.	0.8	41
148	A still missing piece of the FIRE-3 puzzle – Authors' reply. <i>Lancet Oncology</i> , The, 2016, 17, e516.	5.1	1
149	Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. <i>Pancreatology</i> , 2016, 16, 593-598.	0.5	58
150	Safety of palliative chemotherapy in advanced pancreatic cancer. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 947-954.	1.0	8
151	Dosing to rash? – The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash. <i>European Journal of Cancer</i> , 2016, 55, 131-139.	1.3	19
152	Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2585-2591.	1.2	26
153	Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives. <i>Visceral Medicine</i> , 2016, 32, 178-183.	0.5	32
154	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1426-1434.	5.1	336
155	Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. <i>Cancer Medicine</i> , 2016, 5, 2649-2656.	1.3	195
156	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. <i>Lancet Oncology</i> , The, 2016, 17, 1709-1719.	5.1	442
157	Reduced Periprocedural Analgesia After Replacement of Water for Injection with Glucose 5% Solution as the Infusion Medium for <sup>90</sup> Y-Resin Microspheres. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1679-1684.	2.8	15
158	Standards and Challenges of Care for Colorectal Cancer Today. <i>Visceral Medicine</i> , 2016, 32, 156-157.	0.5	12
159	Clinical Significance of TLR1 Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1740-1745.	1.9	9
160	Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head is justified in elderly patients: A Retrospective Cohort Study. <i>International Journal of Surgery</i> , 2016, 28, 118-125.	1.1	46
161	Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 355-360.	2.8	22
162	Reply to G. Nasti and A. Ottaiano and to A. Avallone and A. Budillon. <i>Journal of Clinical Oncology</i> , 2016, 34, 1565-1566.	0.8	2

#	ARTICLE	IF	CITATIONS
163	The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance. <i>Acta Oncologica</i> , 2016, 55, 318-328.	0.8	24
164	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 144-150.	0.8	116
165	Prognostic value of primary tumor resection in synchronous metastatic colorectal cancer (mCRC): Individual patient data (IPD) analysis of first-line randomized trials from the ARCAD database. <i>Journal of Clinical Oncology</i> , 2016, 34, 658-658.	0.8	0
166	NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. <i>International Journal of Cancer</i> , 2015, 137, 678-685.	2.3	94
167	nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. <i>Journal of the National Cancer Institute</i> , 2015, 107, dju413-dju413.	3.0	487
168	Economic evaluation of genetic screening for Lynch syndrome in Germany. <i>Genetics in Medicine</i> , 2015, 17, 765-773.	1.1	40
169	Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and <i>RAS</i> Mutations in Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 692-700.	0.8	686
170	Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). <i>European Journal of Cancer</i> , 2015, 51, 1927-1936.	1.3	150
171	Expression of cancer stem cell markers in metastatic colorectal cancer correlates with liver metastasis, but not with metastasis to the central nervous system. <i>Pathology Research and Practice</i> , 2015, 211, 601-609.	1.0	31
172	Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer—A retrospective analysis of kinetics on 743 breast cancer patients. <i>Clinica Chimica Acta</i> , 2015, 448, 228-231.	0.5	59
173	Brain Metastasis in Colorectal Cancer Patients: Survival and Analysis of Prognostic Factors. <i>Clinical Colorectal Cancer</i> , 2015, 14, 281-290.	1.0	49
174	Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater. <i>Surgery</i> , 2015, 158, 151-161.	1.0	54
175	Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial. <i>BMC Cancer</i> , 2015, 15, 237.	1.1	83
176	Preoperative serum markers for individual patient prognosis in stage III colon cancer. <i>Tumor Biology</i> , 2015, 36, 7897-7906.	0.8	33
177	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2374-2381.	1.9	4
178	High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors. <i>Pharmacogenomics</i> , 2015, 16, 1605-1619.	0.6	7
179	Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With <i>KRAS</i> Wild-Type Tumors in Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3718-3726.	0.8	112
180	Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer. <i>Clinica Chimica Acta</i> , 2015, 440, 16-22.	0.5	49

#	ARTICLE	IF	CITATIONS
181	SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 3502-3502.	0.8	21
182	Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcome of bevacizumab (bev)-based treatment in patients with metastatic colorectal cancer (mCRC): Results from TRIBE and FIRE3 trials.. Journal of Clinical Oncology, 2015, 33, 3552-3552.	0.8	1
183	Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.. Journal of Clinical Oncology, 2015, 33, 515-515.	0.8	1
184	Variations in Y chromosome-related genes and clinical outcome in metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 634-634.	0.8	6
185	Neonax (AIO-PAK-0313): Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: A phase II study of the AIO Pancreatic Cancer Group.. Journal of Clinical Oncology, 2015, 33, TPS497-TPS497.	0.8	2
186	Cetuximab-induced skin rash: A molecular map relating polymorphisms, cell-adhesion, and autoimmunity.. Journal of Clinical Oncology, 2015, 33, 570-570.	0.8	1
187	A phase I, dose-finding study of orally administered S-1 in combination with epirubicin and oxaliplatin (EOS) in patients (pts) with advanced or metastatic gastrointestinal cancer (AGIC) and chemona-ve advanced esophagogastric cancer (AEGC).. Journal of Clinical Oncology, 2015, 33, 140-140.	0.8	0
188	Macrophage polarization related gene variants to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (bev) in combination with FOLFIRI.. Journal of Clinical Oncology, 2015, 33, 621-621.	0.8	0
189	Genetic variant of TWEAK to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and Bevacizumab (FOLFIRI/BEV) in FIRE-3 and TRIBE cohorts.. Journal of Clinical Oncology, 2015, 33, 3554-3554.	0.8	0
190	TREAT-ME 1: Treatment of advanced gastrointestinal cancer in a clinical phase I/II trial with genetically modified mesenchymal stem cells: Clinical results of a phase I study.. Journal of Clinical Oncology, 2015, 33, e13535-e13535.	0.8	0
191	Treatment until progression: Data of the "non-treatment" population of the FIRE-3 (AIO KRK-0306) study.. Journal of Clinical Oncology, 2015, 33, 3589-3589.	0.8	0
192	Baseline carcinoembryonic antigen (CEA) serum levels to predict bevacizumab-based treatment response in patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving 1st-line therapy with FOLFIRI plus cetuximab or bevacizumab (AIO KRK0306, FIRE3 trial).. Journal of Clinical Oncology, 2015, 33, 3581-3581.	0.8	0
193	Genetic variants of kinases suppressors of Ras (KSR) to predict tumor response to first-line cetuximab in patients with mCRC: Prospective analysis in the FIRE 3 trial.. Journal of Clinical Oncology, 2015, 33, 3613-3613.	0.8	0
194	Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405.. Journal of Clinical Oncology, 2015, 33, 3585-3585.	0.8	0
195	The histone deacetylase complex as a drugable target in colorectal cancer.. Journal of Clinical Oncology, 2015, 33, e22200-e22200.	0.8	0
196	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2014, 15, 1065-1075.	5.1	1,479
197	Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer. Clinica Chimica Acta, 2014, 430, 86-91.	0.5	15
198	Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. European Journal of Cancer, 2014, 50, 1855-1863.	1.3	46

#	ARTICLE	IF	CITATIONS
199	Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: Translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. <i>European Journal of Cancer</i> , 2014, 50, 1891-1899.	1.3	31
200	Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3505-3505.	0.8	41
201	Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3506-3506.	0.8	40
202	Amphiregulin (AREG) SNP rs161511 to predict cetuximab efficacy independent of AREG mRNA levels: Data from FIRE3 (AIO KRK-0306).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3521-3521.	0.8	1
203	Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE) Tj ETQq1 b3784314 rgBT /Ove	0.8	1
204	Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3600-3600.	0.8	51
205	Genetic variants of TCF7L2 and AXIN2 predict gender and tumor location-dependent clinical outcome in FIRE-3 trial: A validation study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3602-3602.	0.8	1
206	HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4073-4073.	0.8	36
207	Phase II study of the MEK inhibitor refametinib (BAY 86-9766) in combination with gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer: Biomarker results.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4129-4129.	0.8	2
208	TREAT-ME 1: Treatment of advanced gastrointestinal cancer in a clinical phase I/II trial with genetically modified mesenchymal stem cells.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3122-TPS3122.	0.8	1
209	Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , 2014, 32, 178-178.	0.8	17
210	Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3 A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 445-445.	0.8	61
211	Translational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts. <i>World Journal of Gastroenterology</i> , 2014, 20, 10769.	1.4	20
212	Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4027-4027.	0.8	2
213	AIO KRK0306, FIRE3 trial: CEA and CA19-9 influence outcome of patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving first-line therapy with FOLFIRI plus cetuximab or bevacizumab.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3592-3592.	0.8	0
214	Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4025-4025.	0.8	3
215	Influence of mRNA expression of epieregulin (EREG) and of amphiregulin (AREG) and RAS mutationson outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3522-3522.	0.8	1
216	Biomarker validation study: Genes involved in ubiquitin proteasome system (UPS) dependent EGFR-degradation for prediction of efficacy in metastatic colorectal cancer patients treated with cetuximab.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3571-3571.	0.8	0

#	ARTICLE	IF	CITATIONS
217	Long-term progression-free survival in a metastatic pancreatic cancer patient treated with first-line nab-paclitaxel and gemcitabine. <i>In Vivo</i> , 2014, 28, 1189-92.	0.6	3
218	Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the "Arbeitsgemeinschaft Internistische Onkologie" (AIO-PK0104). <i>Gut</i> , 2013, 62, 751-759.	6.1	105
219	Quantitative analysis of the impact of deepness of response on post-progression survival time following first-line treatment in patients with mCRC.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3630-3630.	0.8	7
220	Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA3506-LBA3506.	0.8	49
221	Deepness of response: A quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC.. <i>Journal of Clinical Oncology</i> , 2013, 31, 427-427.	0.8	21
222	Course of calcium and magnesium serum levels in cetuximab-treated patients: Relation to concurrent chemotherapy and possible predictive value.. <i>Journal of Clinical Oncology</i> , 2013, 31, 521-521.	0.8	0
223	Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104).. <i>Journal of Clinical Oncology</i> , 2013, 31, 189-189.	0.8	0
224	A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following RO/R1 hepatic metastasectomy.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS3124-TPS3124.	0.8	0
225	Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA3506-LBA3506.	0.8	21
226	Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and a prospective evaluation of the of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4007-4007.	0.8	4
227	LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases—a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial. <i>BMC Cancer</i> , 2012, 12, 144.	1.1	16
228	Systemic treatment of advanced pancreatic cancer. <i>Cancer Treatment Reviews</i> , 2012, 38, 843-853.	3.4	108
229	Improved early prediction of individual prognosis for patients with mCRC: Joint modeling of tumor shrinkage with volume data for PFS and OS.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3603-3603.	0.8	3
230	A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): Phase I dose-escalation results.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4050-4050.	0.8	6
231	Validating the prognostic relevance of initial change in tumor size using a series of therapeutic regimens for patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 580-580.	0.8	4
232	Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the AIO KRK 0104 trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3588-3588.	0.8	9
233	Gemcitabine (G) and cisplatin (C) as first-line treatment of metastatic breast cancer (MBC): Results of phase II trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11528-e11528.	0.8	0
234	Capecitabine (cape)-associated hand-foot skin reaction (HFS) as a clinical predictor of improved survival in patients (pts) with colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3541-3541.	0.8	1

#	ARTICLE	IF	CITATIONS
235	A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of L-BLP25 in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.. Journal of Clinical Oncology, 2012, 30, TPS3641-TPS3641.	0.8	0
236	Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KKR-0104â€”A Randomized Trial of the German AIO CRC Study Group. Journal of Clinical Oncology, 2011, 29, 1050-1058.	0.8	99
237	Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer. Oncology, 2010, 79, 118-128.	0.9	21
238	Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treatment Reviews, 2009, 35, 262-271.	3.4	184
239	Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. European Journal of Cancer, 2009, 45, 1117-1128.	1.3	77
240	Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. Gastrointestinal Cancer Research: GCR, 2009, 3, S43-7.	0.8	2
241	Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer, 2008, 8, 82.	1.1	377
242	Definition of An Optimal First-line Chemotherapy in Metastatic Breast Cancer. Breast Cancer Research and Treatment, 2003, 81, 43-48.	1.1	3
243	Present and future treatment of pancreatic cancer. Seminars in Oncology, 2002, 29, 23-31.	0.8	45
244	Gemcitabine in the treatment of advanced pancreatic cancer: A comparative analysis of randomized trials. Seminars in Oncology, 2002, 29, 9-16.	0.8	102
245	Interventional radiological procedures in impaired function of surgically implanted catheter-port systems. CardioVascular and Interventional Radiology, 2001, 24, 31-36.	0.9	5